Scion Team Page Image


United by our conviction in the power of therapeutic innovation to improve human health.

Meet the Scion team

The ten companies our team has been part of founding or building over the past ten years have realized uncommon success and, together, have given rise to >15 clinical-stage therapeutics, advanced six promising therapeutics into pivotal clinical trials and have generated >$14 billion in combined public equity value and announced M&A proceeds. We are excited to discover what the future holds.

Aaron Kantoff Headshot 2024 01 22 174126 mkgm

Aaron Kantoff

Managing Partner

Aaron is a founder and Managing Partner of Scion. He has spent over a decade specializing in founding, building and investing in life sciences companies, focusing primarily on therapeutics. Aaron currently serves as a board member of Tourmaline Bio (NASDAQ: TRML), where he has been serving since the company’s inception. Previously, he was a Venture Partner at Medicxi, where he was a founding board member of Centessa Pharmaceuticals PLC (NASDAQ: CNTA) and assisted the team with other privately held therapeutics investments. Before joining Medicxi, he was a co-founder and founding board member of RayzeBio (NASDAQ: RYZB), which was recently acquired by Bristol Myers Squibb (NYSE: BMY).

From 2011 until 2019, Aaron was a Partner at Apple Tree Partners (ATP), a life sciences venture capital firm. At ATP, Aaron was a key member of the therapeutics investment practice, playing a leading role in assembling several ATP portfolio companies, and most notably, serving on the boards of Akero Therapeutics (NASDAQ: AKRO), Corvidia Therapeutics (acquired by Novo Nordisk) and Syntimmune (acquired by Alexion), as well as two privately held companies (Marengo and Ascidian). During his time at ATP, Aaron was also a board observer at Stoke Therapeutics (NASDAQ: STOK) and led many of ATP’s crossover and public biotech investments. Before joining ATP in 2011, Aaron held various roles in private equity and investment banking.

Aaron received a B.S. in Finance and International Business from NYU Stern’s School of Business.